|
| | BISPHENOL A-(3-CHLORO-2-HYDROXYPROPYL)-& Basic information |
| Product Name: | BISPHENOL A-(3-CHLORO-2-HYDROXYPROPYL)-& | | Synonyms: | BISPHENOL A-(3-CHLORO-2-HYDROXYPROPYL)-&;BISPHENOL A 3-CHLORO-2-HYDROXYPROPYL DIH;2-[4-(3-chloro-2-hydroxypropyloxy)phenyl]-2-[4-(2,3-dihydroxypropyloxy)phenyl]propane;BADGE-HCl-H2O, 2-[4-(3-Chloro-2-hydroxypropyloxy)phenyl]-2-[4-(2,3-dihydroxypropyloxy)phenyl]propane;Bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether,2-[4-(3-Chloro-2-hydroxypropyloxy)phenyl]-2-[4-(2,3-dihydroxypropyloxy)phenyl]propane, BADGE-HCl-H2O;BADGE-HCl-H2O;EPI-001;3-[4-[1-[4-(3-Chloro-2-hydroxypropoxy)phenyl]-1-methylethyl]phenoxy]-1,2-propanediol | | CAS: | 227947-06-0 | | MF: | C21H27ClO5 | | MW: | 394.89 | | EINECS: | 200-258-5 | | Product Categories: | | | Mol File: | 227947-06-0.mol |  |
| | BISPHENOL A-(3-CHLORO-2-HYDROXYPROPYL)-& Chemical Properties |
| Melting point | 67 °C | | Boiling point | 601.0±55.0 °C(Predicted) | | density | 1.228±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble15mg/mL, clear | | pka | 13.13±0.20(Predicted) | | form | powder | | color | white to beige |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 | | HS Code | 29072300 |
| | BISPHENOL A-(3-CHLORO-2-HYDROXYPROPYL)-& Usage And Synthesis |
| Uses | EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator that inhibits androgen receptor expression and activity in prostate cancer. It is a novel androgen receptor antagonists that has the potential for treating prostate cancer. | | Definition | ChEBI: Bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether is the (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) diether of bisphenol A; a small molecule that inhibits transactivation of the AR amino-terminal domain (NTD). It has a role as an androgen antagonist. It is an organochlorine compound and a diether. It is functionally related to a bisphenol A and a glycerol. | | Biological Activity | epi-001 is a small-molecule inhibitor of androgen receptor n-terminal domain. epi-001 could target the amino terminal domain of the ar and inhibit the protein-protein interactions which are necessary for ar transcriptional activity. the androgen receptor (ar) is involved in mediating the actions of male sex steroids. amplification and over-expression of androgen receptor gene may result in hormone-refractory prostate cancer [1]. | | in vitro | epi-001 inhibited the ligand-dependent argal4 transcriptional activity in lncap cells and the ligand-independent argal4 transcriptional activity in the crpc c4-2 cell line. in a panel of cell lines, epi-001 treatment decreased the mrna expression level of ar protein after 8 and 16 h treatment, such as androgen sensitive pca, crpc, lncap, c4-2, and lapc4 cell line. epi-001 dose-dependently inhibited the pca/crpc cell growth [2]. | | in vivo | intravenous injection of epi-001 significantly reduced the weight of benign prostates and blocked the growth of prostate cancer xenograft from noncastrated mature mice. epi-001 caused tumor regression of crpc. in male mice bearing lncap xenografts, after treated with epi- 001 by i.v. injection for 2 weeks, the tumor size was less than half of the control group [3]. | | references | andersen r j, mawji n r, wang j, et al. regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor[j]. cancer cell, 2010, 17(6): 535-546.brand l j, olson m e, ravindranathan p, et al. epi-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer[j]. oncotarget, 2015, 6(6): 3811.sadar m d. small molecule inhibitors targeting the “achilles' heel” of androgen receptor activity[j]. cancer research, 2011, 71(4): 1208-1213. |
| | BISPHENOL A-(3-CHLORO-2-HYDROXYPROPYL)-& Preparation Products And Raw materials |
|
